http://www.meresearch.org.uk/our-studies/rituximab-biomarker-study-update/ "Last year, we reported on a newly funded study aimed at developing a biomarker to help predict patients who will respond to treatment with rituximab. Unfortunately, this study will not now be going ahead." "Although we are still waiting for publication of the full trial results, it is likely they will not show any benefit of rituximab in ME/CFS patients. With this in mind, Prof. Patrick and ME Research UK jointly made the decision not to proceed with the immunosignature study since, in these trial patients at least, there would be nothing to show."
